Literature DB >> 15865277

Isolation of infectious cystic fibrosis patients: results of a systematic review.

Ralf-Peter Vonberg1, Petra Gastmeier.   

Abstract

OBJECTIVE: Respiratory tract infections significantly contribute to morbidity and mortality among cystic fibrosis (CF) patients. Therefore, pathogen transmission needs to be prevented. There are several guidelines for the care of CF patients, but no transparent systematic literature review has been published.
METHODS: We conducted a systematic literature review (January 1966 to September 2004) dealing with segregation of CF patients colonized with Burkholderia cepacia species, Pandoraea species, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, or Alcaligenes species. Quality of studies was evaluated by taking patient population size, existence of control-patients, patient randomization, diagnostic approach, and bacteria typing methods into account.
RESULTS: One hundred ninety-nine studies were found. Evidence and quality of 102 publications were evaluated. In 99 publications, recommendations concerning segregation measures for infectious CF patients were determined including a total of 11,576 patients. No randomized, controlled trials had been conducted. Fifty of 56 authors strongly recommended isolation of CF patients infected with B. cepacia or Pandoraea species. In 31 of 39 studies, interpatient spread of Pseudomonas aeruginosa was documented or had been brought to an end by isolation of patients. Only five studies had addressed S. maltophilia or Alcaligenes species.
CONCLUSIONS: Patients colonized with B. cepacia or Pandoraea species are to be separated from noncolonized patients in single rooms. Patients harboring multidrug-resistant Pseudomonas aeruginosa, S. maltophilia, or Alcaligenes species may not share a room with immunocompromised patients, in intensive care units, or with other CF patients anywhere in the hospital.

Entities:  

Mesh:

Year:  2005        PMID: 15865277     DOI: 10.1086/502558

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  13 in total

1.  Evidence that WapB is a 1,2-glucosyltransferase of Pseudomonas aeruginosa involved in Lipopolysaccharide outer core biosynthesis.

Authors:  Dana Kocíncová; Youai Hao; Evgeny Vinogradov; Joseph S Lam
Journal:  J Bacteriol       Date:  2011-03-25       Impact factor: 3.490

2.  Chronic colonization with Pandoraea apista in cystic fibrosis patients determined by repetitive-element-sequence PCR.

Authors:  R M Atkinson; J J Lipuma; D B Rosenbluth; W M Dunne
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

3.  Achromobacter xylosoxidans genomic characterization and correlation of randomly amplified polymorphic DNA profiles with relevant clinical features [corrected] of cystic fibrosis patients.

Authors:  Annarita Magni; Maria Trancassini; Paola Varesi; Valerio Iebba; Anna Curci; Claudia Pecoraro; Giuseppe Cimino; Serena Schippa; Serena Quattrucci
Journal:  J Clin Microbiol       Date:  2010-01-27       Impact factor: 5.948

4.  Protease inhibitors elicit anti-inflammatory effects in CF mice with Pseudomonas aeruginosa acute lung infection.

Authors:  A Sandri; M M Lleo; C Signoretto; M Boaretti; F Boschi
Journal:  Clin Exp Immunol       Date:  2020-10-12       Impact factor: 4.330

5.  Genome Sequences of Two Pandoraea pnomenusa Isolates Recovered 11 Months Apart from a Cystic Fibrosis Patient.

Authors:  Robson Ee; Mark Ambrose; James Lazenby; Paul Williams; Kok-Gan Chan; Louise Roddam
Journal:  Genome Announc       Date:  2015-02-05

6.  A novel method for investigating Burkholderia cenocepacia infections in patients with cystic fibrosis and other chronic diseases of the airways.

Authors:  Christiaan D M Wijers; Ryan Vagedes; Christine Weingart
Journal:  BMC Microbiol       Date:  2016-09-01       Impact factor: 3.605

7.  Discovery of Pyrrolidine-2,3-diones as Novel Inhibitors of P. aeruginosa PBP3.

Authors:  Arancha López-Pérez; Stefan Freischem; Immanuel Grimm; Oliver Weiergräber; Andrew J Dingley; María Pascual López-Alberca; Herbert Waldmann; Waldemar Vollmer; Kamal Kumar; Cuong Vuong
Journal:  Antibiotics (Basel)       Date:  2021-05-04

8.  SNaPaer: a practical single nucleotide polymorphism multiplex assay for genotyping of Pseudomonas aeruginosa.

Authors:  Nadia Eusebio; Tiago Pinheiro; Adelina A Amorim; Fernanda Gamboa; Lucília Saraiva; Leonor Gusmão; António Amorim; Ricardo Araujo
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

9.  Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers.

Authors:  Henrique Douglas M Coutinho; Vivyanne S Falcão-Silva; Gregório Fernandes Gonçalves
Journal:  Int Arch Med       Date:  2008-11-07

10.  Outbreak of Achromobacter xylosoxidans in an Italian Cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains.

Authors:  Maria Trancassini; Valerio Iebba; Nicoletta Citerà; Vanessa Tuccio; Annarita Magni; Paola Varesi; Riccardo V De Biase; Valentina Totino; Floriana Santangelo; Antonella Gagliardi; Serena Schippa
Journal:  Front Microbiol       Date:  2014-04-03       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.